{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:33:02Z","timestamp":1788571982759,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1681\/asn.2017121317","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T09:15:31Z","timestamp":1516871731000},"page":"360-361","source":"Crossref","is-referenced-by-count":32,"title":["Bardoxolone\u2014the Phoenix?"],"prefix":"10.1681","volume":"29","author":[{"given":"Robert D.","family":"Toto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"B1-20230120","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B2-20230120","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"B3-20230120","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"B4-20230120","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"B5-20230120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2012.393","article-title":"The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells","volume":"83","author":"Ding","year":"2013","journal-title":"Kidney Int"},{"key":"B6-20230120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/00498254.2013.852705","article-title":"The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease","volume":"44","author":"Aminzadeh","year":"2014","journal-title":"Xenobiotica"},{"key":"B7-20230120","doi-asserted-by":"crossref","first-page":"F808","DOI":"10.1152\/ajprenal.00376.2012","article-title":"Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects","volume":"304","author":"Zoja","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"B8-20230120","doi-asserted-by":"crossref","first-page":"F1438","DOI":"10.1152\/ajprenal.00387.2012","article-title":"Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity","volume":"304","author":"Chin","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"B9-20230120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"B10-20230120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000362906","article-title":"Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"39","author":"Chin","year":"2014","journal-title":"Am J Nephrol"},{"key":"B11-20230120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J Card Fail"},{"key":"B12-20230120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000486398","article-title":"Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes \u2013 post-hoc analyses from BEACON","volume":"47","author":"Chin Mb","year":"2018","journal-title":"Am J Nephrol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201802000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:30:24Z","timestamp":1786131024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201802000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017121317","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}